Altimmune (ALT) Competitors $3.64 -0.05 (-1.36%) Closing price 04:00 PM EasternExtended Trading$3.67 +0.03 (+0.71%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALT vs. PGEN, ETNB, XERS, ABCL, EVO, COLL, NTLA, CVAC, ELVN, and CALTShould you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Precigen (PGEN), 89BIO (ETNB), Xeris Biopharma (XERS), AbCellera Biologics (ABCL), Evotec (EVO), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), CureVac (CVAC), Enliven Therapeutics (ELVN), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Altimmune vs. Its Competitors Precigen 89BIO Xeris Biopharma AbCellera Biologics Evotec Collegium Pharmaceutical Intellia Therapeutics CureVac Enliven Therapeutics Calliditas Therapeutics AB (publ) Altimmune (NASDAQ:ALT) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability. Which has more volatility & risk, ALT or PGEN? Altimmune has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Does the media refer more to ALT or PGEN? In the previous week, Altimmune had 23 more articles in the media than Precigen. MarketBeat recorded 30 mentions for Altimmune and 7 mentions for Precigen. Precigen's average media sentiment score of 1.53 beat Altimmune's score of 0.30 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 2 Very Positive mention(s) 5 Positive mention(s) 21 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend ALT or PGEN? Altimmune currently has a consensus target price of $17.40, indicating a potential upside of 378.02%. Precigen has a consensus target price of $8.25, indicating a potential upside of 117.68%. Given Altimmune's higher probable upside, research analysts clearly believe Altimmune is more favorable than Precigen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Altimmune 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57Precigen 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do institutionals and insiders believe in ALT or PGEN? 78.1% of Altimmune shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 4.4% of Altimmune shares are held by insiders. Comparatively, 47.1% of Precigen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ALT or PGEN more profitable? Precigen has a net margin of -2,868.66% compared to Altimmune's net margin of -438,730.03%. Altimmune's return on equity of -62.63% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Altimmune-438,730.03% -62.63% -55.29% Precigen -2,868.66%-842.83%-78.98% Which has higher earnings and valuation, ALT or PGEN? Altimmune has higher earnings, but lower revenue than Precigen. Precigen is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAltimmune$20K16,063.32-$95.06M-$1.18-3.08Precigen$3.92M288.09-$126.24M-$0.42-9.02 SummaryAltimmune beats Precigen on 8 of the 15 factors compared between the two stocks. Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALT vs. The Competition Export to ExcelMetricAltimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$325.67M$2.84B$5.79B$10.15BDividend YieldN/A56.65%5.69%4.61%P/E RatioN/A23.5374.5925.92Price / Sales16,063.32534.57449.5483.33Price / CashN/A169.2537.0859.91Price / Book2.095.3712.156.29Net Income-$95.06M$32.95M$3.28B$270.85M7 Day Performance-3.70%1.31%0.98%3.36%1 Month Performance0.55%8.31%7.20%6.41%1 Year Performance-48.73%0.29%63.06%28.26% Altimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTAltimmune2.5582 of 5 stars$3.64-1.4%$17.40+378.0%-48.5%$325.67M$20K0.0050PGENPrecigen4.5646 of 5 stars$4.51-0.9%$8.25+82.9%+325.5%$1.34B$3.92M-10.74190Positive NewsETNB89BIO2.8006 of 5 stars$9.03-4.1%$26.63+194.9%+6.7%$1.34BN/A-2.5040Positive NewsXERSXeris Biopharma3.0333 of 5 stars$7.83-0.9%$7.08-9.5%+168.5%$1.26B$203.07M-37.28290Positive NewsInsider TradeABCLAbCellera Biologics2.4296 of 5 stars$4.18-2.8%$8.00+91.4%+71.4%$1.25B$32.88M-7.60500EVOEvotec1.6822 of 5 stars$3.50-0.3%$5.40+54.3%+1.5%$1.24B$777.33M0.004,827COLLCollegium Pharmaceutical3.7126 of 5 stars$38.80+1.2%$42.33+9.1%+7.9%$1.22B$631.45M37.31210Positive NewsNTLAIntellia Therapeutics4.3194 of 5 stars$11.35-2.2%$29.05+156.0%-43.6%$1.22B$57.88M-2.42600Analyst RevisionCVACCureVac3.9174 of 5 stars$5.37flat$6.83+27.3%+77.9%$1.20B$510.51M5.59880Short Interest ↑ELVNEnliven Therapeutics3.0118 of 5 stars$20.27-0.4%$41.20+103.3%-13.7%$1.20BN/A-10.1450Insider TradeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180News Coverage Related Companies and Tools Related Companies Precigen Alternatives 89BIO Alternatives Xeris Biopharma Alternatives AbCellera Biologics Alternatives Evotec Alternatives Collegium Pharmaceutical Alternatives Intellia Therapeutics Alternatives CureVac Alternatives Enliven Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALT) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALT Stock Alerts